Islamabad: Drug Regulatory Authority of Pakistan (DRAP) ne 400 top-selling non-essential medicine brands ke prices ka comprehensive review karne ke liye bids invite kar diye hain, taake February 2024 ke deregulation ke baad price changes ka pata lagaya ja sake.
Senior DRAP officials ke mutabiq, yeh survey pehle ke 100 brands ke survey ko expand karega, jahan pichle do saalon mein average 32% izafa dekha gaya tha. New survey se regional aur formulation ke farq ko bhi samajhna mumkin hoga.
Survey ke tehat independent consultants ya research firms pharmacies, distributors, hospitals aur clinics se current market prices collect karenge aur pre-deregulation maximum retail prices se compare karenge. Ye exercise Islamabad, Rawalpindi, Lahore, Karachi, Peshawar, Quetta aur Multan mein ki jayegi.
DRAP ka kehna hai ke deregulation ka maqsad manufacturers ko pricing flexibility dena aur medicines ki availability improve karna tha, aur market ko monitor kiya ja raha hai taake policy outcomes ka objective assessment ho sake.
Former Pakistan Pharmaceutical Manufacturers Association chairman Tauqeer ul Haq ke mutabiq price increases ka zyada tar asar inflation, exchange-rate pressures aur production cost ka hai, na ke deregulation ka. Unka kehna hai ke actual post-deregulation price increase modest raha aur medicines ki availability behtar hui hai.
Bids submit karne ki last date December 29, 2025 hai aur sirf electronic submission accept ki jaayegi. Survey ke results relevant stakeholders ke sath share kiye jayenge aur future pricing aur regulatory decisions mein madad denge.
